Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.61%
As of Friday, October 02, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Commentary & Analysis
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.05%
As of Thursday, September 24, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.73%
As of Wednesday, September 23, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 5.73%, which has investors questioning if this is right time to buy.Michael Rose
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.30%
As of Wednesday, September 09, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 5.30%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 6.83%
As of Monday, July 13, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 6.83%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $123.9 | $218.1 | 24% |
|
| Shares Out (Mil) | 60.5 | 53.9 | 52% |
|
| Institutional Ownership | 97.5% | 93.1% | 74% |
|
| Float (Mil) | 44.5 | 40.9 | 44% |
|
| Beta | 1.31 | 0.95 | 76% |
|
| Avg Daily Volume (000s) | 939 | 611 | 69% |
|
| Price Change (52-week) |
(58.9%) | 46.3% | 16% |
|
| Growth | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.1%) | 12.8% | 2% |
|
| Net Income (5yr) | (39.4%) | (10.2%) | 10% |
|
| EPS (5yr) | (32.5%) | 15.7% | 7 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.2%) | (15.7%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.418) | ($1.705) | ($1.279) | |
| Month Ago EPS | ($0.418) | ($1.705) | ($1.279) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($0.475) | ($1.657) | ($1.560) | |
| Year/Year Chg | 3.5% | (16.4%) | (52.9%) | |
| Financials | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($108) | ($44) | 10% |
|
| EPS (TTM) | ($1.812) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($121) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $26 | $4 | 34% |
|
| Enterprise Value (Q1) (Mil) | $85 | $177 | 20% |
|
| Valuation | VYGR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.80 | 2.13 | 18% |
|
| P/E | na | 19.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (236.8%) | 66.0% | 1% |
|
| Net Margin | (312.6%) | (75.3%) | 3% |
|
| ROA | (41.4%) | (47.2%) | 13% |
|
| ROE | (54.1%) | (54.2%) | 15% |
|
| Liabilities to Assets | 21.9% | 29.1% | 14% |
|
| F-Score | 2 | 3 | 7% |
|
Voyager Therapeutics, Inc. did not pass any screens on 10/14/2026.
